- Home
- VIVS vs QLGN Comparison
VIVS vs QLGN Comparison
Compare VIVS & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- QLGN
- Stock Information
- Founded
- VIVS 2007
- QLGN 1996
- Country
- VIVS United States
- QLGN United States
- Employees
- VIVS N/A
- QLGN N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- QLGN Health Care
- Exchange
- VIVS Nasdaq
- QLGN Nasdaq
- Market Cap
- VIVS 8.1M
- QLGN 7.4M
- IPO Year
- VIVS N/A
- QLGN N/A
- Fundamental
- Price
- VIVS $2.28
- QLGN $2.75
- Analyst Decision
- VIVS
- QLGN
- Analyst Count
- VIVS 0
- QLGN 0
- Target Price
- VIVS N/A
- QLGN N/A
- AVG Volume (30 Days)
- VIVS 104.1K
- QLGN 3.4M
- Earning Date
- VIVS 11-12-2025
- QLGN 11-13-2025
- Dividend Yield
- VIVS N/A
- QLGN N/A
- EPS Growth
- VIVS N/A
- QLGN N/A
- EPS
- VIVS N/A
- QLGN N/A
- Revenue
- VIVS $142,000.00
- QLGN N/A
- Revenue This Year
- VIVS $42.38
- QLGN N/A
- Revenue Next Year
- VIVS $15.42
- QLGN N/A
- P/E Ratio
- VIVS N/A
- QLGN N/A
- Revenue Growth
- VIVS 94.52
- QLGN N/A
- 52 Week Low
- VIVS $1.41
- QLGN $1.61
- 52 Week High
- VIVS $21.96
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- VIVS 38.84
- QLGN 37.21
- Support Level
- VIVS $2.14
- QLGN $3.28
- Resistance Level
- VIVS $2.44
- QLGN $5.97
- Average True Range (ATR)
- VIVS 0.27
- QLGN 0.57
- MACD
- VIVS -0.09
- QLGN -0.22
- Stochastic Oscillator
- VIVS 10.00
- QLGN 1.23
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.